The WilmerHale capital markets practice is recognised for its strength in equity transactions across the life sciences and technology sectors. The team represents both issuers and investment banking firms in IPOs, follow-on offerings, PIPE placements, and Rule 144A transactions. New York-based Brian Johnson brings particular expertise in compliance and disclosure matters. Also based in New York is Lisa Firenze who is well versed in spin-offs, convertible note offerings and SPAC transactions. Caroline Dotolo is recognised for her strength in mergers and acquisitions, while Judith Hasko and Mick Bain offer practice on a broad range of corporate transactions.
Legal 500 Editorial commentary
Key clients
- Solid Biosciences Inc.
- Cue Biopharma, Inc.
- Akebia Therapeutics, Inc.
- State Street Corporation
- Strategy Inc
- Xilio Therapeutics, Inc.
- Beam Therapeutics Inc.
- Dyne Therapeutics, Inc.
- Trevi Therapeutics, Inc.
Work highlights
Advised Strategy Inc, in connection with several at-the-market offerings, with total proceeds of approximately $10.5 billion.
Advised Beam Therapeutics Inc. in its underwritten registered direct offering of its common stock and pre-funded warrants, with proceeds of approximately $500 million.
Advised Dyne Therapeutics, Inc. in transactions securing up to $505 million of debt and equity capital, including a $275 million senior secured debt financing with Hercules Capital, Inc., as agent and lender, and a concurrent $230 million underwritten public offering of common stock.
Other key lawyers
Judith Hasko; Mick Bain; Brian Johnson; Lisa Firenze; Caroline Dotolo